Project Details
Projekt Print View

How Golgi lipids drive growth factor signaling at the plasma membrane

Subject Area Cell Biology
Term from 2009 to 2013
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 156980886
 
Final Report Year 2015

Final Report Abstract

Triple-negative breast cancers (TNBCs) are especially refractory to treatment due to their negative hormone receptor and ErbB2/HER2 status. Therefore, the identification of cancer-associated deregulated signaling pathways is necessary to develop improved targeted therapies. In this project we revealed that the expression of the ceramide transfer protein CERT is reduced in TNBCs. CERT transfers ceramide from the endoplasmic reticulum to the Golgi complex for conversion into sphingomyelin (SM). We provide evidence that by regulating cellular SM levels, CERT determines the signaling output of the epidermal growth factor receptor (EGFR/ErbB1), which is upregulated in approximately 70% of TNBCs. CERT downregulation in breast cancer cells enhanced ErbB1 lateral mobility, ligand-induced autophosphorylation, internalization and chemotaxis. Together, our findings provide a link between lipid metabolism at the Golgi with signaling at the plasma membrane, thereby implicating CERT loss in the progression of TNBCs. Finally, considering that SM reduction compromises Fas/CD95 death receptor activation, CERT downregulation is likely to have a broad impact on cellular signalling characteristics, which are not restricted to the EGFR/ErbB1.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung